UNSPSC 51172411: Amylase/papain

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA500. This VA Drug Class (GA500) classifies this compound as belonging to the group DIGESTANTS.

UNSPSC 51172411 Amylase/papain is a Commodity code covering pharmaceutical and diagnostic enzymes procured by state and local health and criminal justice agencies. Recent solicitations show state and local governments buying amylase and papain primarily as components of drug-testing panels, immunoassay screening systems, and multi-source pharmaceutical supply agreements. The issuing bodies span state health commissions, county criminal justice and community supervision departments, and cooperative purchasing alliances aggregating demand across multiple state and local jurisdictions. Collin County Community Supervision and Corrections Department (Texas) and the Texas Health and Human Services Commission represent repeat buyers in the recent opportunity stream, along with multistate cooperative vehicles such as the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), which coordinates pharmaceutical procurement for participating state and local government facilities across Oregon, Minnesota, and other jurisdictions.

Recent opportunities center on two primary procurement patterns. Collin County issued RFP 2026-327 for offender specimen collection and drug testing services (due July 23, 2026, estimated value $600,000 over two years) requiring immunoassay screening with enzyme-based panel testing—five-panel and six-panel screens administered approximately 25,031 times annually—along with LC/MS/MS or GC/MS confirmation and alternative testing methodologies. The Texas Health and Human Services Commission issued RFI HHS0017013 in late March 2026 to gather vendor capabilities for direct-to-manufacturer pharmaceutical procurement, signaling upstream sourcing interest beyond traditional pharmacy benefit manager channels. MMCAP issued RFP S1070000015802 (due March 26, 2026) to establish contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local facilities, requiring vendors to maintain relationships with AmerisourceBergen (Cencora), Cardinal Health, and Morris & Dickson as authorized wholesalers, with pricing weighted at 75 percent of evaluation and contract effectiveness targeted for July 1, 2026. Procurement activity concentrates in Texas and the upper Midwest (Minnesota, Oregon) among state departments, county justice agencies, and regional cooperative purchasing entities.